Global sales and Copaxone lift Teva
This article was originally published in Scrip
Executive Summary
In reviewing its financial results for the year, Teva Pharmaceutical Industries' chief executive Shlomo Yanai called 2010 "a great year for Teva", in which the firm became the generics leader in Europe, moved to complete its integration of the German company Ratiopharm, increased its presence in emerging markets, and had record sales of its multiple sclerosis drug Copaxone (glatiramer acetate).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.